The dry powder inhaler market is projected to experience significant growth, with an estimated value of USD 20.83 billion in 2024. This market is anticipated to reach approximately USD 29.95 billion by 2034, reflecting a compound annual growth rate (CAGR) of 3.70% over the next decade.
This growth can be attributed to several factors, including the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), which drive demand for effective and user-friendly delivery systems. Dry powder inhalers (DPIs) offer numerous advantages, including portability, ease of use, and the absence of propellants, making them a preferred choice for many patients and healthcare providers.
Moreover, advancements in inhalation technology and ongoing innovations in formulation development are enhancing the effectiveness and patient compliance associated with dry powder inhalers. As healthcare professionals continue to prioritize patient-centric solutions, the demand for DPIs is expected to rise steadily.
In summary, the dry powder inhaler market is poised for robust growth, driven by increasing demand for respiratory disease management and ongoing technological advancements. Industry stakeholders are encouraged to invest in research and development to enhance product offerings and meet the evolving needs of patients and healthcare providers.
This growth is driven by the increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and the rising demand for efficient and user-friendly inhalation therapies. Dry powder inhalers are gaining popularity due to their ease of use, portability, and ability to deliver medication effectively to the lungs.
This anticipated growth underscores the increasing demand for effective respiratory treatment solutions, driven by rising prevalence of chronic respiratory conditions and advancements in inhaler technology. Dry powder inhalers have become a crucial component in managing diseases such as asthma and chronic obstructive pulmonary disease (COPD), offering patients a convenient and efficient method for drug delivery.
The DPI market’s expansion is fueled by continuous innovations in inhaler design and formulation, aimed at improving patient adherence and therapeutic outcomes. Enhanced features, such as improved drug delivery mechanisms and user-friendly designs, are contributing to the market’s upward trajectory.
This growth trajectory reflects the increasing adoption of dry powder inhalers as a preferred method for delivering respiratory medications. The market’s expansion is supported by ongoing advancements in DPI technology, improved patient compliance, and the rising prevalence of respiratory conditions.
hallenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers
Regulatory pressures and changes in the drug delivery market have driven the innovation of the dry powder inhaler forward.
According to the World Health Organization (WHO), nearly 300 million people worldwide are affected by asthma, and approximately 240 Mn by chronic obstructive pulmonary disease (COPD).
Over half of these patients combined prefer the use of dry powder inhalers for the treatment of their disease.
These devices have depicted great potential in effective and reliable drug delivery, with novel designs ensuring the possibility to overcome future compliance, cost, and safety challenges.
Some of the essential performance characteristics regarding dry powder inhalers are associated with dose delivery, performances at varying airflows, and fine particle fraction content.
These characteristics may vary for powder formulations, creating the need for fine-tuning of the device or powder formulation or both combined for achieving optimal performance.
The requirement is particularly high in micro-dosing dry powder inhalers, which in turn is paving opportunities for medical device manufacturers in terms of innovations and advancements.
Growing adoption of unhealthy lifestyles, increasing geriatric population, and growing air pollution levels fuelling the prevalence of various respiratory disorders are key factors driving the expansion of the global powder inhaler market.
In addition, favorable government initiatives being taken across the globe to improve the healthcare infrastructure will further influence the market growth.
However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties when it comes in contact with moisture.
The availability of effective alternatives such as nebulizers and electric pumps is expected to restrain the adoption of dry powder inhalers.
Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.
Key Research Findings from FMI’s Report on the Dry Powder Inhaler Market
- The dry powder inhaler market is a sizeable and established industry, exceeding US$20 billion in 2024.
- The market is anticipated to witness consistent growth, with a projected CAGR of 3.70% over the next decade.
- This translates to a market value surpassing US$29.95 billion by 2034, indicating potential for stakeholders.
Leading companies in the Global Dry Powder Inhaler Industry are focusing on the development of new-generation products.
These market players are making huge investments in R&D activities associated with novel device architectures, particle engineering, and powder formulations.
Key Segments Covered In Dry Powder Inhaler Market Research
By Product:
- Single Dose Dry Powder Inhalers
- Multi-Dose Dry Powder Inhalers
By Indication:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Arterial Hypertension
- Diabetes
- Cystic Fibrosis
By Function:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
By End User:
- Institutional Sales
- Hospital Pharmacies
- Cancer Research
- Office-based Speciality Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube